Phase 1b & 2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (VIRO-15)

Trial ID # NCT02759588; VIRO-15
Phase Ib/II
Drug Class Oncolytic Viruses
Drug Name Olvimulogene nanivacirepvec
Alternate Drug Names light-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1
Drugs in Trial Bevacizumab, Carboplatin, Docetaxel, Liposomal doxorubicin, Olvimulogene nanivacirepvec, Paclitaxel, Gemcitabine
Eligible Participant

Platinum resistant or platinum refractory ovarian cancer

Patients Enrolled

Phase I: 12 patients; Phase II: 27 patients, median 4 prior therapies (2-9); 48% Pt-R, 52% Pt-Rf

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, DoR, PFS, OS, evaluated per RECIST


Olvi-Vec alone: 12 patients, median 5 prior therapies (2-10)
ORR: 9% (1PR, n=11)
DCR: 73% (1PR, 7SD, n=11)
PFS: 3.9 months

Olvi-Vec+CarboPt-based therapy w/ or w/o Bev:
ORR: 54% (2CR, 11PR, n=24)
DCR: 87.5% (2CR, 11PR, 8SD, n=24)
DoR: 7.6 months
PFS: 11.0 months
PFS (6 months): 77%
OS: 15.7 months

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE: overall (14.8%)


Patients treated with IP Olvi-Vec-primed immunochemotherapy combined with standard carboplatinum based therapy shows ORR and PFS exceeding historical comparisons and patients’ own last prior therapy. The majority of patients benefit from apparent reversal of platinum resistance


Holloway RW et al. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. JAMA Oncol (2023) 9(7):903-908

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.